ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

Inclusion Criteria:

• Chronic kidney disease defined by one of the below:

1. Estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 15and below 60 mL/min/1.73 m^2 (using the Chronic Kidney Disease EpidemiologyCollaboration (CKD-EPI) creatinine equation)

2. Urinary albumin-to-creatinine ratio (UACR) >= 200 milligrams per gram (mg/g)and eGFR >= 60 mL/min/1.73 m2 (using the CKD-EPI creatinine equation)

• Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2milligram per liter (mg/L)

• Evidence of atherosclerotic cardiovascular disease (ASCVD) by one or more of thefollowing: a) Coronary heart disease defined as at least one of the following: i. Documentedhistory of MI ii. Prior coronary revascularisation procedure iii. greater than orequal to 50% stenosis in major epicardial coronary artery documented by cardiaccatheterisation or CT coronary angiography b) Cerebrovascular disease defined as atleast one of the following: i. Prior stroke of atherosclerotic origin ii. Priorcarotid artery revascularisation procedure iii. greater than or equal to 50%stenosis in carotid artery documented by X-ray angiography, MR angiography, CTangiography or Doppler ultrasound. c) Symptomatic peripheral artery disease (PAD) defined as at least one of thefollowing: i. Intermittent claudication with an ankle-brachial index (ABI) below orequal to 0.90 at rest ii. Intermittent claudication with a greater than or equal to 50% stenosis in peripheral artery (excluding carotid) documented by X-rayangiography, MR angiography, CT angiography or Doppler ultrasound iii. Priorperipheral artery (excluding carotid) revascularisation procedure iv. Lowerextremity amputation at or above ankle due to atherosclerotic disease (excludinge.g. trauma or osteomyelitis).

Exclusion Criteria:

• Clinical evidence of, or suspicion of, active infection at the discretion of theinvestigator.

• Myocardial infarction, stroke, hospitalisation for unstable angina pectoris, ortransient ischaemic attack within 60 days prior to randomisation (visit 2).

• Planned coronary, carotid or peripheral artery revascularisation known on the day ofrandomisation (visit 2).

• Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2).